Special Issue

Immunotherapy of Solid Tumors: Progress, Challenges, and Future Roadmap

Message from the Guest Editors

Immunotherapy can either work by restimulating the patient's immune system to recognize and attack the cancer-associated self-antigens or by passively transferring immune molecules or cells that can directly destroy cancer cells. It is essential to understand the physical, biochemical, and immunological challenges associated with solid malignancies to evaluate immunotherapy-based treatment approaches more critically and conclusively. This Special Issue aims to focus on understanding the ongoing challenges in optimizing immunotherapies for solid malignancies and highlighting endeavors to overcome such roadblocks. Studies in this issue will provide a future roadmap to optimize and evaluate immunotherapies to treat solid malignancies. We look forward to your contributions.

Guest Editors

Dr. Shailendra Gautam Department of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA

Dr. Abhijit Aithal Department of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA

Deadline for manuscript submissions

closed (31 May 2023)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/123675

Vaccines Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 vaccines@mdpi.com

mdpi.com/journal/

vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



vaccines



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).